INGRESAR
CREAR CUENTA
Artículos
Puesta al día | 02 MAR 21

Carcinoma hepatocelular

Nuevos avances en la vigilancia, diagnóstico y tratamiento del carcinoma hepatocelular.
1
Autor/a: Ju Dong Yang, Julie K Heimbach. PMID: 33106289 DOI: 10.1136/bmj.m3544
INDICE:  1. Texto principal | 2. Texto principal
Texto principal
  1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16:589-604. doi:10.1038/s41575-019-0186-y 
  2. Fitzmaurice C, Allen C, Barber RM, et al, Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 2017;3:524-48. doi:10.1001/jamaoncol.2016.5688 
  3. Yang JD, Harmsen WS, Slettedahl SW, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol 2011;9:617-23.e1. doi:10.1016/j. cgh.2011.03.027 
  4. Yang JD, Kim WR, Park KW, et al. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology 2012;56:614-21. doi:10.1002/hep.25680 
  5. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624. doi:10.1371/journal.pmed.1001624 
  6. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018;154:1706- 1718.e1. doi:10.1053/j.gastro.2018.01.064 
  7. Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev 2014;23:144-53. doi:10.1158/1055-9965.EPI-13-0870 
  8. Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol 2016;14:875-886.e6. doi:10.1016/j.cgh.2015.12.042 
  9. Best J, Bechmann LP, Sowa JP, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2020;18:728-735.e4. doi:10.1016/j.cgh.2019.11.012 
  10. Ahn JC, Teng PC, Chen PJ, et al. Detection of circulating tumor cells and their implications as a novel biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology 2020. doi:10.1002/hep.31165 
  11. Yang JD, Liu MC, Kisiel JB. Circulating tumor DNA and hepatocellular carcinoma. Semin Liver Dis 2019;39:452-62. doi:10.1055/s-0039-1688503 
  12. Rich NE, Yopp AC, Singal AG, Murphy CC. Hepatocellular carcinoma incidence is decreasing among younger adults in the United States. Clin Gastroenterol Hepatol 2020;18:242-248.e5. doi:10.1016/j. cgh.2019.04.043 
  13. Shiels MS, O’Brien TR. Recent decline in hepatocellular carcinoma rates in the United States. Gastroenterology 2020;158:1503-1505. e2. doi:10.1053/j.gastro.2019.12.030 
  14. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-1273.e1. doi:10.1053/j.gastro.2011.12.061 
  15. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553-62. doi:10.1038/nrgastro.2013.107
  16. Yang JD, Kim WR. Surveillance for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2012;10:16-21. doi:10.1016/j.cgh.2011.06.004 
  17. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417- 22. doi:10.1007/s00432-004-0552-0 
  18. Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?Hepatology 2011;54:1998-2004. doi:10.1002/hep.24581 
  19. Yang JD, Mannalithara A, Piscitello AJ, et al. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology 2018;68:78-88. doi:10.1002/hep.29594 
  20. Hanouneh IA, Alkhouri N, Singal AG. Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?Clin Mol Hepatol 2019;25:264-9. doi:10.3350/cmh.2019.1001
  21. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50. doi:10.1002/hep.29913
  22. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma [correction in: J Hepatol 2019;70:817]. J Hepatol 2018;69:182-236.
  23. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-70. doi:10.1007/s12072-017- 9799-9 
  24. Ioannou GN, Green PK, Berry K. HCV eradication induced by directacting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 2017;S0168-8278(17)32273-0.
  25. Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016;64:800-6. doi:10.1016/j.jhep.2015.11.035
  26. Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience. Dig Dis Sci 2015;60:3142-8. doi:10.1007/s10620-015-3821-7 
  27. Kanwal F, Kramer JR, Mapakshi S, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 2018;155:1828-1837.e2. doi:10.1053/j. gastro.2018.08.024
  28. Loomba R, Lim JK, Patton H, El-Serag HB. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Gastroenterology 2020;158:1822-30. doi:10.1053/j. gastro.2019.12.053 
  29. Choi DT, Kum HC, Park S, et al. Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis. Clin Gastroenterol Hepatol 2019;17:976-987.e4. doi:10.1016/j. cgh.2018.10.031
  30. Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol 2015;21:11567-83. doi:10.3748/wjg.v21.i41.11567
  31. Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:169-77. doi:10.1111/apt.13841 
  32. Kim SY, An J, Lim YS, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol 2017;3:456-63. doi:10.1001/ jamaoncol.2016.3147
  33. Kim HL, An J, Park JA, Park SH, Lim YS, Lee EK. Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis. Hepatology 2019;69:1599-613. doi:10.1002/hep.30330
  34. Khatri G, Pedrosa I, Ananthakrishnan L, et al. Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI-RADS v2018. J Magn Reson Imaging 2020;51:415- 25. doi:10.1002/jmri.26835 
  35. Lee JY, Huo EJ, Weinstein S, et al. Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:1627-33. doi:10.1007/ s00261-017-1339-5 
  36. Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography -- a randomised study. Aliment Pharmacol Ther 2013;38:303-12. doi:10.1111/apt.12370 
  37. Yang JD, Addissie BD, Mara KC, et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev 2019;28:531-8. doi:10.1158/1055-9965.EPI-18-0281 
  38. Kisiel JB, Dukek BA, Kanipakam RVSR, et al. Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I pilot, and phase II clinical validation. Hepatology 2019;69:1180-92. doi:10.1002/hep.30244 
  39. Terzi E, Iavarone M, Pompili M, et al, CEUS LI-RADS Italy study group collaborators. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. J Hepatol 2018;68:485-92. doi:10.1016/j. jhep.2017.11.007 
  40. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91. doi:10.1200/ JCO.2008.20.7753 
  41. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27. . doi:10.1056/NEJMra1001683 
  42. Ramai D, Ofosu A, Lai JK, Reddy M, Adler DG. Combined Hepatocellular Cholangiocarcinoma: A Population-Based Retrospective Study. Am J Gastroenterol 2019;114:1496-501. doi:10.14309/ajg.0000000000000326 
  43. Zhang J, Mavros MN, Cosgrove D, et al. Impact of a single-day multidisciplinary clinic on the management of patients with liver tumours. Curr Oncol 2013;20:e123-31. doi:10.3747/co.20.1297 
  44. Serper M, Taddei TH, Mehta R, et al, VOCAL Study Group. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology 2017;152:1954-64. doi:10.1053/j. gastro.2017.02.040 
  45. Sinn DH, Choi GS, Park HC, et al. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS One 2019;14:e0210730. doi:10.1371/journal. pone.0210730 
  46. Tian G, Yang S, Yuan J, et al. Comparative efficacy of treatment strategies for hepatocellular carcinoma: systematic review and network meta-analysis. BMJ Open 2018;8:e021269. doi:10.1136/ bmjopen-2017-021269 
  47. Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev 2013;(12):CD003046. doi:10.1002/14651858.CD003046. pub3
  48.   Ng KKC, Chok KSH, Chan ACY, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for earlystage hepatocellular carcinoma. Br J Surg 2017;104:1775-84. doi:10.1002/bjs.10677 
  49. Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010;252:903-12. doi:10.1097/ SLA.0b013e3181efc656 
  50. Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012;57:794-802. doi:10.1016/j.jhep.2012.05.007 
  51. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-8. doi:10.1097/01.sla.0000201480.65519. b8 
  52. Liu H, Wang ZG, Fu SY, et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br J Surg 2016;103:348-56. doi:10.1002/bjs.10061 }
  53. Yin L, Li H, Li AJ, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol 2014;61:82-8. doi:10.1016/j.jhep.2014.03.012 
  54. Pompili M, Saviano A, de Matthaeis N, et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey. J Hepatol 2013;59:89-97. doi:10.1016/j.jhep.2013.03.009 
  55. Cheung TT, Dai WC, Tsang SH, et al. Pure laparoscopic hepatectomy versus open hepatectomy for hepatocellular carcinoma in 110 patients with liver cirrhosis: a propensity analysis at a single center. Ann Surg 2016;264:612-20. doi:10.1097/ SLA.0000000000001848 
  56. Yoon YI, Kim KH, Kang SH, et al. Pure laparoscopic versus open right hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a propensity score matched analysis. Ann Surg 2017;265:856-63. doi:10.1097/SLA.0000000000002072 
  57. Sposito C, Battiston C, Facciorusso A, et al. Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma. Br J Surg 2016;103:871-80. doi:10.1002/bjs.10137 
  58.  Deng ZC, Jiang WZ, Tang XD, Liu SH, Qin L, Qian HX. Laparoscopic hepatectomy versus open hepatectomy for hepatocellular carcinoma in 157 patients: A case controlled study with propensity score matching at two Chinese centres. Int J Surg 2018;56:203-7. doi:10.1016/j.ijsu.2018.06.026 
  59. Kokudo T, Hasegawa K, Matsuyama Y, et al, Liver Cancer Study Group of Japan. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol 2016;65:938-43. doi:10.1016/j.jhep.2016.05.044 
  60. Liang L, Chen TH, Li C, et al. A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus. HPB (Oxford) 2018;20:1119-29. doi:10.1016/j.hpb.2018.06.1804 
  61. Chong JU, Choi GH, Han DH, et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol 2018;25:3308-15. doi:10.1245/ s10434-018-6653-9 
  62. Bruix J, Takayama T, Mazzaferro V, et al, STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebocontrolled trial. Lancet Oncol 2015;16:1344-54. doi:10.1016/ S1470-2045(15)00198-9 
  63. Gabr A, Abouchaleh N, Ali R, et al. Outcomes of surgical resection after radioembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2018;29:1502-1510.e1. doi:10.1016/j.jvir.2018.06.027  64 
  64. Labgaa I, Tabrizian P, Titano J, et al. Fea
  65. sibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma. HPB (Oxford) 2019;21:1497-504. doi:10.1016/j.hpb.2019.03.360}Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9. doi:10.1056/ NEJM199603143341104 
  66. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007;7:2587-96. doi:10.1111/j.1600- 6143.2007.01965.x 
  67. Mazzaferro V, Llovet JM, Miceli R, et al, Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43. doi:10.1016/ S1470-2045(08)70284-5
  68. Sapisochin G, Goldaracena N, Laurence JM, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology 2016;64:2077-88. doi:10.1002/hep.28643
  69. Toso C, Meeberg G, Hernandez-Alejandro R, et al. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology 2015;62:158-65. doi:10.1002/hep.27787 
  70. Kaido T, Ogawa K, Mori A, et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver tran
« Página anterior
 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

CONTENIDOS RELACIONADOS
Pruebas de cirrosis
Enfermedad del hígado graso no alcohólico
» Centro de Atención IntraMed
AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024